Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 10/20 | 0.60 |
| ▸ | BCHE | P06276 | 9/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062372 | 0.83 | KDM5A (1.00) | KDM5ATDP1HTTGAAMAPT | |
| SCHEMBL9926442 | 0.75 | BCHE (1.00) | ACHEBCHEMAPT | |
| SCHEMBL9208663 | 0.75 | HTT (0.74) | ACHEBCHEHTTGAAMAPT | |
| SCHEMBL27838000 | 0.74 | ACHE (0.57) | ACHEBCHE | |
| SCHEMBL8476129 | 0.74 | HTT (0.73) | ACHEBCHEHTTGAAMAPT | |
| SCHEMBL8473136 | 0.74 | HTT (0.69) | ACHEBCHEHTTGAAMAPT | |
| SCHEMBL15946336 | 0.74 | ACHE (0.50) | TDP1ACHEBCHEHTTGAA | |
| SCHEMBL8474173 | 0.73 | BCHE (0.66) | ACHEBCHEHTTGAAMAPT | |
| SCHEMBL7945036 | 0.73 | BCHE (0.65) | ACHEBCHE | |
| SCHEMBL10061487 | 0.73 | HTT (0.67) | ACHEBCHEHTTGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853920-B1 | FLUORESCENCE POLARIZATION ASSAYS FOR ACETYLTRANSFERASE/DEACETYLASE ACTIVITY | SIRTRIS PHARMACEUTICALS INC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080293081-A1 | Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293081-A1 | Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | KDM5A 971/4885TDP1 667/4885ACHE 1167/4885 |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | KDM5A 1060/4885TDP1 262/4885ACHE 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.